← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #397 OF 1,000 MOST-CITED

Accurate, indelible, legible

FDA cited this observation 49 times across 44 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Human Tissue for Transplantation49
BY FISCAL YEAR
FY20262
FY20259
FY20247
FY202310
FY20222
FY20211
FY20204
FY20195
FY20188
FY20171

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 0.8× the rate of the average FDA-cited firm (6.8% vs 8.3%), across 44 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…

How FDA worded it — real examples

Donor eligibility records are not accurate.

Southwest Fertility Center · Phoenix, Arizona · Human Tissue for Transplantation · 2026-04-14

Donor eligibility records are not accurate.

Aligneage Fertility Laboratory, LLC · New York, New York · Human Tissue for Transplantation · 2025-10-21

Records were not accurate.

Hans Biomed Corporation · Yuseong District · Human Tissue for Transplantation · 2025-09-12

Records were not accurate.

Eurofins Donor & Product Testing, LLC, San Ramon · San Ramon, California · Human Tissue for Transplantation · 2025-07-18

Donor eligibility records are not accurate, indelible and legible.

Fort Worth Fertility P.A. · Fort Worth, Texas · Human Tissue for Transplantation · 2025-04-24

Donor eligibility records are not accurate, indelible and legible.

Kofinas Fertility Group · New York, New York · Human Tissue for Transplantation · 2025-04-09

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →